Published in Eur J Haematol on August 06, 2008
A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation. J Biomed Biotechnol (2009) 1.05
Mechanisms of hepatocyte growth factor activation in cancer tissues. Cancers (Basel) (2014) 0.94
Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol (2012) 0.84
In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib. Int J Clin Exp Pathol (2014) 0.77
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood (2016) 0.77
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol (2017) 0.75
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J (1992) 2.65
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem (2000) 2.47
Emerging multipotent aspects of hepatocyte growth factor. J Biochem (1996) 2.34
Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol (1993) 2.14
Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol (2006) 2.06
Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol (2002) 1.64
Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem (1993) 1.57
Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica (2005) 1.52
The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia (2003) 1.37
Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood (1998) 1.35
HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood (2007) 1.32
Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem (1993) 1.21
Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev (2003) 1.19
Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood (2005) 1.16
A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res (2004) 1.15
Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator. Eur J Biochem (1995) 1.14
Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res (2000) 1.05
Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood (2004) 0.99
Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo. Int J Cancer (2006) 0.91
Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica (2008) 0.91
Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. Eur Urol (2005) 0.85
Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. FEBS J (2008) 0.85
Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (1987) 7.24
Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med (1992) 4.02
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol (2000) 2.49
[Laparoscopic hepatectomy]. Ann Chir (2002) 2.41
Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood (1998) 1.83
Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol (1989) 1.76
Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia (2006) 1.63
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol (2009) 1.58
Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol (2001) 1.58
Elevated plasma levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome. J Infect Dis (1996) 1.54
Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood (2000) 1.54
Dual endoscopic-assisted endoluminal colostomy reversal: a feasibility study. Surg Endosc (2004) 1.50
Cytokine regulation of interleukin 6 production by human endothelial cells. Cell Immunol (1989) 1.46
Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med (1990) 1.39
Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction. Heart (2005) 1.38
[A young woman with adverse effects of neuroleptics]. Tidsskr Nor Laegeforen (2009) 1.38
Tumor necrosis factor, interleukin-1, and interleukin-6 in normal human pregnancy. Am J Obstet Gynecol (1993) 1.37
High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun (1995) 1.36
Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood (1998) 1.35
Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol (1986) 1.29
TNF receptors in murine Candida albicans infection: evidence for an important role of TNF receptor p55 in antifungal defense. J Immunol (1996) 1.24
Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect Immun (1992) 1.22
The involvement of CD14 in stimulation of cytokine production by uronic acid polymers. Eur J Immunol (1993) 1.18
Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood (2001) 1.15
Tumor necrosis factor receptor p75 mediates cell-specific activation of nuclear factor kappa B and induction of human cytomegalovirus enhancer. J Biol Chem (1994) 1.13
Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. Ann Oncol (1995) 1.10
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood (2001) 1.10
Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood (1996) 1.09
[A national registry for cholecystectomy. Quality assurance with practical consequences?]. Tidsskr Nor Laegeforen (1995) 1.09
Evidence that diphtheria toxin and modeccin enter the cytosol from different vesicular compartments. J Cell Biol (1984) 1.08
Syndecan-1 in B lymphoid malignancies. Ann Hematol (2002) 1.07
Similar mechanisms of action of defined polysaccharides and lipopolysaccharides: characterization of binding and tumor necrosis factor alpha induction. Infect Immun (1993) 1.06
Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem (1996) 1.06
Effect of potassium depletion of cells on their sensitivity to diphtheria toxin and pseudomonas toxin. J Cell Physiol (1985) 1.05
High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood (2000) 1.05
Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. Lancet (1990) 1.05
Regulation of interleukin-2 and interleukin-6 production from T-cells: involvement of interleukin-1 beta and transforming growth factor-beta. Cell Immunol (1990) 1.04
Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. J Infect Dis (1993) 1.02
Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem (1996) 1.01
Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells. Oncogene (2011) 1.00
Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+ natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12. Eur J Immunol (1993) 1.00
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol (2003) 0.99
Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia (2011) 0.99
Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood (1999) 0.98
Receptor-mediated endocytosis of a ricin-colloidal gold conjugate in vero cells. Intracellular routing to vacuolar and tubulo-vesicular portions of the endosomal system. Exp Cell Res (1985) 0.98
Induction of tumor necrosis factor production from monocytes stimulated with mannuronic acid polymers and involvement of lipopolysaccharide-binding protein, CD14, and bactericidal/permeability-increasing factor. Infect Immun (1997) 0.96
Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine (1999) 0.95
Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol (2000) 0.91
Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock. Microb Pathog (1992) 0.91
Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J Urol (1998) 0.90
Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res (1999) 0.90
Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine (1997) 0.90
Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. Eur J Immunol (1995) 0.90
Cytokine-associated tissue injury and lethality in mice: a comparative study. Clin Immunol Immunopathol (1991) 0.90
Activation of adult human derived microglia by myelin phagocytosis in vitro. J Neurosci Res (1994) 0.89
Influence of CD14, LBP and BPI in the monocyte response to LPS of different polysaccharide chain length. Scand J Immunol (1995) 0.89
TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol (1994) 0.89
Calmodulin antagonists sensitize cells to pseudomonas toxin. J Cell Physiol (1984) 0.88
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol (1999) 0.88
Pulmonary embolism: detection with MR perfusion imaging of lung--a feasibility study. Radiology (1997) 0.87
Preparation and properties of chimeric toxins prepared from the constituent polypeptides of diphtheria toxin and ricin. Evidence for entry of ricin A-chain via the diphtheria toxin pathway. J Biol Chem (1982) 0.87
Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. Br J Haematol (1999) 0.86
Involvement of the tumor necrosis factor receptor p75 in mediating cytotoxicity and gene regulating activities. Eur J Immunol (1994) 0.86
Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitus. Acta Diabetol (1998) 0.86
Bile leak after cholecystectomy significance and treatment: results from the National Norwegian Cholecystectomy Registry. Int Surg (1997) 0.86
Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol (2001) 0.86
The inflammatory response following treatment of abdominal aortic aneurysms: a comparison between open surgery and endovascular repair. Eur J Vasc Endovasc Surg (2000) 0.85
Involvement of CD14 and beta2-integrins in activating cells with soluble and particulate lipopolysaccharides and mannuronic acid polymers. Infect Immun (2000) 0.85
Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol (1995) 0.84
Antigen presentation by human fetal astrocytes with the cooperative effect of microglia or the microglial-derived cytokine IL-1. J Neurosci (1995) 0.84
A population-based survey of biliary surgery in Norway. Relationship between patient volume and quality of surgical treatment. Surg Endosc (1998) 0.84
Effects of polysaccharide fucoidin on cerebrospinal fluid interleukin-1 and tumor necrosis factor alpha in pneumococcal meningitis in the rabbit. Infect Immun (1999) 0.83
Interleukin-1, interleukin-6 and tumor necrosis factor at delivery in preeclamptic disorders. Acta Obstet Gynecol Scand (1995) 0.83
Tumor necrosis factor induces lipopolysaccharide tolerance in a human adenocarcinoma cell line mainly through the TNF p55 receptor. J Biol Chem (1995) 0.83
A closed-chest pulmonary artery occlusion/reperfusion model in the pig: detection of experimental pulmonary embolism with MR angiography and perfusion MR imaging. Invest Radiol (2000) 0.83
Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation. Cytokine (1993) 0.83
Tumour necrosis factor and septic shock. Lancet (1998) 0.82